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Key Points
• BCR subsets 2 and 8 show
specific genetic profiles
influencing CLL course.
Genetic lesions and B-cell receptor (BCR) signaling are both oncogenic drivers in
chronic lymphocytic leukemia (CLL). However, scant data are available on preferential
associations between specific genetic alterations and stereotyped BCR subsets. By
analyzing 1419 cases, 2 CLL subsets (2 and 8) harboring stereotyped BCR are enriched
in specific molecular alterations influencing disease course. SF3B1 mutations are the
genetic hallmark of IGHV3-21-CLL belonging to subset 2 (52%) but are evenly represented
in nonstereotyped IGHV3-21-CLL. Trisomy 12 (87%) and NOTCH1 mutations (62%) characterize IGHV4-39-CLL belonging to subset 8
but occur with the expected frequency in IGHV4-39-CLL with heterogeneous BCR. Clinically, co-occurrence of SF3B1 mutations and
subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, 112,
and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome. These findings provide a proof of
concept that specific stereotyped BCRmay promote or select molecular lesions influencing outcome. (Blood. 2013;121(24):4902-4905)
Introduction
Driver genetic lesions in chronic lymphocytic leukemia (CLL) include
recurrent chromosomal aberrations and point mutations affecting
the TP53, NOTCH1, SF3B1, BIRC3, and MYD88 genes.1-7 Genetic
abnormalities arise at the time of neoplastic transformation and
during clonal evolution likely following various microenvironmental
signals, including those provided by the B-cell receptor (BCR).8
CLL often carries surface BCR with similar stereotypic patterns
resulting from IGHV-IGHD-IGHJ rearrangements already present
in the natural B-cell repertoire of normal individuals prior to trans-
formation, thus suggesting that recognition of common epitopes or
classes of structurally similar epitopes is likely involved in leukemic
clone selection.9-12 So far, more than 200 different subsets have been
deﬁned with stereotyped BCR, with 8 subsets (1-8) accounting for
;30% of all stereotyped CLL.10
Despite the established role of genetics and BCR features in the
pathobiology of CLL, little is known regarding the association
between speciﬁc genetic aberrations and distinct CLL subsets with
stereotyped BCR.13,14 By investigating a large cohort of more than
1400 CLL cases, here we report that 2 CLL immunogenetic subgroups
with proven prognostic/predictive relevance (stereotyped BCR subsets
2 and 8)15-17 show a subset-speciﬁc genetic proﬁle inﬂuencing
disease course. Our results point to the potential role of speciﬁc
stereotyped BCR patterns in promoting the occurrence or selection
of genetic lesions that impact on clinical outcome of CLL.
Study design
Samples
The study was based on 1419 newly diagnosed CLL cases (supplemental
Figure 1 and Table 1; see theBloodWeb site). According to sample size analysis,
the number of cases was sufﬁcient to allow identiﬁcation of all possible genetic
lesions co-occurring with each of the most represented BCR subsets (ie, those
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including.5 cases) (power, 80%; a-error, 0.5). The study was approved by the
institutional ethical committee (Protocol Code 59/CE; Study Number CE 8/11).
Patients provided informed consent in accordance with local Institutional
Review Board requirements and the Declaration of Helsinki.
Molecular studies
Molecular studies were performed on biological samples collected at the
time of CLL diagnosis. IGHV-IGHD-IGHJ and IGLV-J rearrangements,
and mutations of the TP53, NOTCH1, SF3B1, MYD88, and BIRC3 genes
were analyzed by Sanger sequencing.5,7,17 Probes used for ﬂuorescence in
situ hybridization were the following: (1) LSID13S319, CEP12, LSIp53,
and LSIATM (Abbott); and (2) RP11-177O8 (BIRC3) BAC clone.7 Further
details of the molecular studies are available in the supplemental Appendix.
Statistical analysis
Immunoglobulin heavy variable gene complementarity determining region
3 sequences from our CLL data set (supplemental Tables 2 and 3) and from
public CLL databases were aligned, and stereotyped rearrangements were
clustered according to a previously reported bioinformatic algorithm.10
The binomial distribution of the frequency of the genetic lesions within
each of the 8 most represented BCR subsets was calculated according to
the p of the genetic lesions in IGHV-mutated or IGHV-unmutated CLL,
depending on the IGHV mutation status that preferentially or exclusively
associated with a given BCR subset. Deviations of the observed binomial
distribution from the theoretically expected binomial distribution were
assessed by the nonparametric binomial test. All statistical tests were
2-sided, and P values were corrected for multiple comparisons using the
Bonferroni method. Statistical signiﬁcance was deﬁned as P , .05. The
analysis was performed with SPSS software v20.0 (Chicago, IL). Further
details of the statistical analysis are available in the supplemental Appendix.
Results and discussion
To uncover the interactions between molecular lesions of cancer
genes and BCR-driven mechanisms in CLL, we performed a cross-
sectional investigation of the associations between the most recurrent
mutations (TP53, NOTCH1, SF3B1, BIRC3, and MYD88), chromo-
somal abnormalities (del17p, del11q, del13q, 112, and BIRC3
deletion), and BCR features in 1419 newly presented CLL cases.
The molecular and immunogenetic features of the study cohort were
consistent with those expected in newly diagnosed CLL (supplemental
Figures 2A and 3). The overall frequency of BCR stereotypy (21.4%)
was in the range of that reported in CLL series of similar size.18,19
The genetics of CLL differed according to IGHV mutation status,
as documented by the signiﬁcantly higher prevalence of favorable
lesions in IGHV-mutated CLL and of unfavorable lesions in IGHV-
unmutated cases (supplemental Figure 2B). On the contrary, after
compensating for IGHV mutation status, BCR stereotypy did not
Figure 1. Distribution of CLL driver genetic lesions across major stereotyped BCR subsets. (A) Circos plot representing the relative frequency and pairwise co-
occurrence of CLL driver genetic lesions and usage of stereotyped BCR belonging to majors subsets (1, 2, 3, 4, 5, 6, 7B, and 8) in newly diagnosed CLL. The length of the arc
corresponds to the frequency of the genetic lesions. The width of the ribbon corresponds to the percentage of patients in which the 2 connected variables co-occur. (B)
Prevalence of CLL driver genetic lesions within the major BCR subsets (1, 2, 3, 4, 5, 6, 7B, and 8) in newly diagnosed CLL. p, P value from the nonparametric binomial test;
p corrected, P value from the nonparametric binomial test corrected for multiple hypothesis testing.
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affect the distribution of genetic lesions (supplemental Figure 4).
Although IGHV-unmutated CLL showed a broad association with all
unfavorable genetic lesions, expression of zeta-chain-associated pro-
tein kinase 70 and CD38, 2 molecules that may cooperate with the
BCR in CLL,1 appeared to cluster with speciﬁc genetic subgroups
(supplemental Figure 5). Overall, these data are consistent with
the notion that (1) IGHV mutation status, but not BCR stereotypy
as a whole, distinguishes different clinical and biological subgroups
of CLL; (2) not only BCR stereotypy, but also molecular genetics is
highly dependent on IGHV mutational status in CLL; and (3) different
components of the CLL signaling machinery may favor distinct
genetic events in this leukemia.
Consistent with previous reports, BCR subsets 1 to 8 were the most
represented in this CLL cohort, overall accounting for ;30% of all
stereotyped cases.10 Twomajor subsets, namely, subsets 2 (IGHV3-21)
and 8 (IGHV4-39), recurrently showed a distinctive pattern of mole-
cular alterations (Figure 1A-B). In contrast, in all the other major
subsets the prevalence of genetic lesions did not differ signiﬁcantly
from what was expected based on chance alone (Figure 1A-B).
Compared with other major BCR subsets, CLL subset 2 was
signiﬁcantly enriched in SF3B1 mutations, which occurred in 45.4%
of cases (P 5 1.58 3 1024) (Figure 1A-B). The prevalence of
SF3B1 mutations was higher when the analysis was restricted to
subset 2 cases utilizing both the IGHV3-21 and IGHVL3-21 genes
(52.6%). In contrast, IGHV3-21-CLL with heterogeneous BCR
displayed a signiﬁcantly lower prevalence of SF3B1 mutations
(13.8%; P 5 .002) (supplemental Figure 6A), thus suggesting that
the association between subset 2 and SF3B1 mutations is driven by
the homology in the BCR rather than mere usage of the IGHV3-21
gene. Of note, subset 2 CLL consistently lacked TP53 abnormalities,
which were otherwise evenly represented in all the other major
subsets (Figure 1A-B). This observation is in agreement with the
known anticorrelation between SF3B1 and TP53 lesions in CLL
and points to SF3B1 mutations, rather than TP53 abnormalities, as
the main driver of progressiveness in subset 2 CLL.5
Consistently, subset 2 CLL harboring SF3B1 mutations showed
a higher progression rate to a disease requiring treatment (5-year
treatment-free survival [TFS], 33.3%) compared with subset 2 CLL
harboring a wild-type SF3B1 (5-year TFS, 62.5%; P 5 .064) and
to IGHV3-21-CLL with heterogeneous BCR (5-year TFS, 54.6%;
P5 .076) (Figure 2A). These data suggest that, among IGHV3-21-
CLL, the association between SF3B1 mutations and subset 2 BCR
conﬁguration contributes to promote disease progression, rather
than the sole stereotypic features of IGHV3-21–bearing BCR.
Subset 8 CLL was signiﬁcantly enriched in112, which occurred
in 87.5% of cases (P 5 9.6 3 1024) (Figure 1A-B). Consistent
with the relationship between112 and NOTCH1 lesions,20,21 subset
8 CLL was also enriched in NOTCH1 mutations (62.5% of cases),
although at a borderline signiﬁcance probably due to sample size.
The prevalence of 112 and NOTCH1 mutations was signiﬁcantly
higher in subset 8 CLL than in IGHV4-39-CLL with nonstereotyped
BCR (112, 27.9%, P5 .003; NOTCH1mutations, 8.1%, P5 .006;
supplemental Figure 6B), implying that these genetic-immunogenetic
associations are inﬂuenced by the homology in the BCR rather than
shared usage of the IGHV4-39 gene.
From a clinical standpoint, as already documented in a partially
overlapping CLL cohort,17 the majority (5/8, 62.5%) of patients
belonging to subset 8 had transformed to Richter syndrome. All
transformed cases carried both NOTCH1 mutations and112, whereas
this genetic association was never observed among subset 8 patients
that had not transformed to Richter syndrome (P 5 .017)
(Figure 2B). These data indicate a cooperation between NOTCH1
mutations, 112, and subset 8 BCR conﬁguration in priming
Richter syndrome transformation.22,23
Figure 2. Clinical impact of the genotype in stereotyped BCR subset 2 and subset 8 CLL. (A) Kaplan-Meier estimates of TFS according to SF3B1mutation status in CLL
utilizing the IGHV3-21 gene. (B) Heat map showing the relationship between genetic lesions and Richter syndrome transformation in subset 8 CLL. Rows correspond to
identical variables, and columns represent individual patients color-coded based on the molecular status (white, absence of the variable; red, presence of the variable).
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Taken together, our observations provide a proof of concept
that speciﬁc BCR conﬁgurations may contribute to clonal selection of
speciﬁc genetic lesions in CLL. Although our analysis was focused
on the most represented BCR subsets, the interaction between BCR
conﬁguration and speciﬁc genetic lesions might be a more general
phenomenon in CLL. In order to extend this observation also to
minor BCR subsets, investigation of large case series of thousands
of CLL patients is warranted. In addition, our data prompt studies
aimed at assessing the role of BCR signaling in clonal evolution
and selection of speciﬁc genetic abnormalities in lymphoid tumors,
nonneoplastic conditions,24 and normal B-cell subsets25 bearing
stereotyped BCR.
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